Across TCGA pan-cancer cohorts, MKKS mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MKKS data layer compared with 21 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MKKS mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MKKS expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.
CCRCC and GBM are the cancer types where MKKS mass-spec protein most reproducibly stratifies survival.